August 24, 2018
Ranier's Compounding Laboratory is voluntarily recalling bevacizumab 1.25 mg/0.05 mL prefilled syringes because of concerns about sterility, according to the August 22, 2018, US Food and Drug Administration (FDA) Enforcement Report.
The prefilled syringes were distributed in Pennsylvania, and the recall affects all lots within expiry.
Ranier's Compounding Laboratory initiated the recall July 25, 2018. The FDA designated the recall Class II August 15, 2018. Use of the affected syringes may cause temporary or medically reversible adverse health consequences, according to the classification, or a remote possibility of serious harm.
Bevacizumab is a prescription chemotherapy drug used to treat several types of cancer.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here